This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (2)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Bioterrorism  • Alert me on articles by topic  Social Bookmarking   What's this?

Brian Vastag

JAMA. 2002;287:1516-1517.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Washington—The nation's only anthrax vaccine, mandatory for most military personnel since 1998, is as safe as any other vaccine and will prevent infection from inhaled spores, concludes an extensive report issued by the Institute of Medicine (IOM) early this month. However, the report committee made it clear that the vaccine should be given only to those at high risk for exposure. Last fall's anthrax attacks left some physicians in a quandary when panicked patients demanded the vaccine.

These main conclusions were darkened by the report committee's concern about the vaccine's inadequacies, including an 18-month immunization schedule, painful subcutaneous delivery, and outdated design. Manufactured by Bioport Corp, Lansing, Mich, the vaccine was developed in the 1950s at Camp Detrick (now Fort Detrick), Maryland, which at the time housed a biological weapons program.

While fears of attacks from similar weapons prompted the military to adopt the vaccine, the injections . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

The Cost-Effectiveness of Strategies to Reduce Mortality from an Intentional Release of Aerosolized Anthrax Spores
Braithwaite et al.
Med Decis Making 2006;26:182-193.
ABSTRACT